Fig 1.
The flow diagram of the present phase II clinical study.
Table 1.
Patient Characteristics at baseline (N = 69).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; MBC, metastatic breast cancer.
Fig 2.
Kaplan–Meier plot of PFS (a) and OS (b) for all patients and Kaplan-Meier plot of PFS (c) and OS (d) in patients with ORR versus non-ORR.
Fig 3.
Waterfall plot of the maximum change in tumor size showed best overall responses in each patient.
Table 2.
Note: This table included AEs occurring between the date of the first dose and 30 days following the last dose of study treatment. Abbreviations: AEs, adverse events; NA, not applicable.